H1N1 vaccine by Pandemrix® poses risk to people with known hypersensitivity

[Guest guest]

H1N1 vaccine by Pandemrix® poses risk to people with known

hypersensitivity

November 4, 2009 by Susie Collins

_http://www.thecanaryreport.org/2009/11/04/h1n1-vaccine-by-pandemrix%c2%ae-p

oses-risk-to-people-with-known-hypersensitivity/_

(http://www.thecanaryreport.org/2009/11/04/h1n1-vaccine-by-pandemrix®-poses-ris\

k-to-people-with-known-

hypersensitivity/)

 

Environmental physicians in Germany say H1N1 vaccine by Pandemrix® is

unsuitable for patients with chronic multi-system illnesses.

 

CSN: Chemical Sensitivity Network reports the German Professional

Association of Environmental Medicine advises against the H1N1 vaccine by

Pandemrix® for people with chronic multi-system illnesses.

 

 

Press release of the German Professional Association of Environmental

Medicine (Deutscher Berufsverband der Umweltmediziner – DBU).

From 26. October 2009.

 

 

Swine flu [H1N1] vaccine is unsuitable for patients with chronic

multi-system illnesses. Pandemrix® poses substantial health risk with respect

to

mass immunization programs due to the lack of proof of safety. Because of the

producer’s release from liability by the German Federal Government (BRD),

the risk of adverse reactions and/or permanent damage due to the vaccine

rests with the patient.

 

 

The German Professional Association of Environmental Medicine (DBU) has,

in spite of press releases from the BRD, the Paul-Ehrlich-Institute, as well

as the vaccine producer’s assurances of safety, serious concerns relating

to Pandemrix® (GlaxoSmithKline), the only vaccine which has been approved

for mass vaccination by the BRD.

 

 

The DBU discusses at this point neither the medical use of immunization in

general nor the necessity of such measures in the, up until now, mild

course of the swine flu pandemic.

 

 

Our criticism is directed only against the pandemic vaccine Pandemrix®.

 

-- There exists considerable doubt as to the effectiveness of the vaccine:

during the licensing phase, the vaccine tested had a 40% higher portion of

virus antigen (5. 25µg) than the vaccine (3.75µg) now being delivered. An

unequivocal consensus has not been reached as to whether the vaccination

should be given once or twice a season.

 

-- There exists considerable doubt concerning the safety of the adjuvanted

active amplifier since it is being used for the first time. The vaccine

contains 27.4mg AS03, an emulsion of polysorbate, squalene and tocopherol.

Sufficient studies are lacking, because in the test phase, only the

development of antibody titers was determined as a surrogate criterion, and not

any

potential adverse reactions.

 

-- The producer as well as government agencies have concealed the fact

that squalene, if used subcutaneously or intramuscularly is an inflammatory

immune activation immunogen, unlike when ingested. (Squalene is, among other

things, for example, naturally contained in olive oil.)

 

-- Autoimmune diseases can be provoked by squalene; already existing ones

can be activated. Squalene has been connected with the emergence of

Guillan-Barré Syndrome (GBS) and is now considered a trigger for Gulf War

Syndrome

(GWS). In animal studies squalene brought on rheumatoid arthritis.

 

-- Squalene from food sources is mainly incorporated into membranes in the

body. The production of squaline antibodies resulting from an immunization

sets off chronic inflammation of the membranes, which explains diseases

such as Gulf War Syndrome and also degenerative neurological diseases such as

Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Chronic Inflammatory

Demyelinating Polyneuropathy and Guillan-Barré Syndrome.

 

-- The delivery of vaccine in multiple dose ampules is obsolete. In single

dose ampules the mercury used for preservation, as in thimerosal – which

is included in Pandemrix – would be unnecessary. Also, mercury has been

proven to set off autoimmune diseases.

 

-- Since the vaccine has not been tested on either young children or

pregnant women (Ethics Commission objection), the call to give preference in

the

first phase of vaccination to precisely this particularly endangered

segment of the population represents an improper and totally unjustifiable

field

test.

 

-- The vaccine poses a higher risk than the swine flu itself for patients

with environmental illness and for patients with compromised immune systems

(e.g. AIDS).

 

-- The vaccine producer GlaxoSmithKline (GSK), according to the contract

with the BRD, is largely exempt from liability. In case of damage from the

vaccination, the affected vaccinee would have to sue the government and

therefore the country of Germany, usually a futile exercise.

 

-- To avoid the trap of liability, the doctor giving the vaccination must

meticulously inform the patient of all risks concerning the vaccination and

the vaccine. It is recommended to give this information in the presence of

an assistant and to have it be confirmed by the patient’s signature. The

explanation should also include the liability features. Also the indication

that other, lower risk vaccines are available in Europe and that due to a

faulty decision by the German government, they are currently not available to

the German population. This information should definitely be included in

the explanation.

 

 

For general and environmental health considerations the DBU urgently

advises against carrying out a vaccination with Pandemrix®.

 

Dr.med. Hans-Peter Donate for the board of the German Professional

Association of Environmental Medicine (DBU)

 

 

For more information on Pandemrix®, here is the manufacturer’s summary of

product characteristics

_http://www.emea.europa.eu/humandocs/PDFs/EPAR/pandemrix/emea-combined-h832e

n.pdf_

(http://www.emea.europa.eu/humandocs/PDFs/EPAR/pandemrix/emea-combined-h832en.pd\

f)

 

 

Here is a quick look at one section on possible side effects:

 

**Caution is needed when administering this vaccine to persons with a

known hypersensitivity (other than anaphylactic reaction) to the active

substance, to any of the excipients, to thiomersal and to residues (egg and

chicken protein, ovalbumin, formaldehyde, gentamicin sulphate and sodium

deoxycholate). **

 

 

(http://www.papercut.biz/emailStripper.htm)